INTRINSIC RV - Inhibition of Unnecessary RV Pacing With AV Search Hysteresis in ICDs
Phase 4
Completed
- Conditions
- Tachycardia
- Registration Number
- NCT00148967
- Lead Sponsor
- Boston Scientific Corporation
- Brief Summary
INTRINSIC RV is a two-armed randomized trial that will compare the effects of innovative dual-chamber pacing with AV Search Hysteresis to standard VVI among ICD patients.
- Detailed Description
The purpose of study is to assess whether AVSH will provide benefits of a dual-chamber ICD without the deleterious effects of unnecessary RV pacing. This study will aim to demonstrate that DDDR-AVSH is equal to VVI with respect to mortality and HF hospitalizations.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1535
Inclusion Criteria
- Patients who meet VITALITY™AVT® ICD indications
- Patients who sign and date a Patient Informed Consent prior to device implant
- Patients who remain in the clinical care of the enrolling physician
Exclusion Criteria
- Patients with current indication for CRT-D
- Patients who previously had a pacemaker, ICD or CRT-D
- Patients with chronic AF
- Patients whose life expectancy is <12 months due to other medical conditions
- Patients who are expected to receive a heart transplant during the duration of the study
- Patients with epicardial pacing leads
- Patients who have CABG, PCI, cardiac or other arrhythmia surgery planned but not yet performed
- Patients with or who are likely to receive a tricuspid or other valve prosthesis
- Patients who are currently enrolled in another investigational study that would directly impact the treatment or outcome of the current study
- Patients who are younger than 18 years of age
- Patients who are pregnant
- Patients who are mentally incompetent and cannot give Patient Informed Consent or participate in the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Primary Outcome Measures
Name Time Method Demonstrate that DDDR-AVSH is as effective as VVI with respect to the composite endpoint of death or heart failure hospitalizations.
- Secondary Outcome Measures
Name Time Method The following variables will be compared between patients who are randomized to either DDDR-AVSH or VVI: The prevalence of atrial fibrillation, Changes in medication dosage, including beta-blocker, anti-arrhythmic and coumadin medications, Programming changes, Quality of life